{
  "hadm_id": "21468812",
  "note_id": "14636748-DS-20",
  "note": " \nName:  ___                   Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \ncefazolin / ceftaroline fosamil / Flagyl\n \nAttending: ___.\n \nChief Complaint:\nAcute hypoxic resp distress\n \nMajor Surgical or Invasive Procedure:\nNone\n\n \nHistory of Present Illness:\n___ with past medical history of AFib recently started\non warfarin, AS s/p bioprosthetic AVR, CAD s/p CABG (LIMA-LAD,\nSVG-RCA), severe OSA, HTN, T2DM c/b peripheral neuropathy, b/l\nknee replacements, and recent hospitalization from ___ for\nrhabdomyolysis, acute embolic CVA from aortic arch atheroma, and\nMSSA/S. hominus bacteremia and recurrent admission from \n___\nfor acute on chronic hypoxic resp failure and MSSA PNA requiring\nintubation, multi-organ dysfunction, and recurrent MSSA\nbacteremia (thought to be from R ___ toe osteo) discharged on 6\nweek course of cephazoline who represented on ___ from rehab\n for a rash c/f leukocytoclastic vasculitis ___ infection vs.\ncefazolin, found to have CoNS/Bacillus bacteremia c/f \ncontaminant\nvs. PICC line infection treated with vanc, HFpEF exacerbation,\npseudomonas UTI, ___, course c/b severe C diff (___), slow GIB\nthought to be due C diff, VRE bacteremia (thought from GI\ntranslocation and endocarditis) on dapto and ceftaroline, and\nmost recently severe thrombycytopenia thought to be drug-induced\nfrom antibiotics who developed an episode of hemoptysis \nyesterday\nand developed acute on chronic hypoxic respiratory failure\nrequiring transfer to the MICU, thought to be related to DAH. \n\nPer primary team, on ___ patient had precipitous drop in\nplatelets from 156 -> 23 of initially unclear etiology. Heme/onc\nwas consulted and feel this is not likely a hemolytic process \nand\nmost likely drug-induced from either flagyl or ceftaroline (both\nstopped). HIT antibody screen negative, fibrinogen and\nhaptoglobin normal. On ___, patient had an episode of \nhemoptysis\nwhere he coughed up a quarter-sized clot but was otherwise\nstable. He received platelet transfusions on ___ and ___ with\ntorsemide due to concern for ongoing slow GI bleed and episode \nof\nhemoptysis respectively. On morning of ___, patient developed\nacute hypoxic respiratory distress requiring non-rebreather for\ndesaturations down to ___. Labs were notable for a slightly\nincreased leukocytosis to 10 from 8.4, stable hgb, VBG 7.25/60.\nCXR at time of decompensation showed pulm vascular congestion \nand\npossible worsening R-sided consolidation. \n\n \nPast Medical History:\nAfib (recently restarted on warfarin iso emboli)\nAortic valve replacement \nPeripheral vascular disease\nHFpEF\nEmbolic CVA (___)\nDM \nHTN\nArthritis \nBilateral knee replacement\nL femur fracture - surgical repair\n___ Admission to ___ for multiorgan failure, course c/b \nmultiple brain emboli thought to be from aortic atheroma. Course \ncomplicated by MSSA bloodstream infection, Afib with RVR, \nrhabdomyolysis leading to acute renal failure requiring HD, and \nlater NSTEMI.  Recovered renal function. \n\n \nSocial History:\n___\nFamily History:\nNot pertinent to presenting problem.\n \nPhysical Exam:\nADMISSION PHYSICAL EXAM\n=======================\nPHYSICAL EXAM:  \nVITALS: T 97.8, BP 157/94, HR 131, RR 26, SpO2 100 on 4L NC \nGeneral: Alert, oriented, interactive, improved from yesteray\nHEENT: Sclerae anicteric, small petechiae on lips, neck supple,\nJVP 9cm \nCV: Tachycardic, irregular rhythm, normal S1 + S2, no murmurs,\nrubs, gallops  \nLungs: Dimished breath sounds throughout. Crackles in bilateral\nbases. \nAbdomen: Soft, non-tender, non-distended, bowel sounds present,\nno organomegaly, no rebound or guarding  \nGU: No foley  \nExt: Warm, well perfused, 2+ pulses, no clubbing, cyanosis or\nedema. Amputated ___ R toes with dried blood under dressing. \nAlso\nwith amputated L third toe.  \nNeuro: Face grossly symmetric. Moving all limbs with purpose\nagainst gravity. Not dysarthric.  \n\nDISCHARGE PHYSICAL EXAM\n=======================\nGeneral: Alert, oriented, interactive\nHEENT: Sclerae anicteric, small petechiae on lips, neck supple\nCV: irregular and fast rhythm, normal S1 + S2, no murmurs,\nrubs, gallops  \nLungs: CTAB. No crackles appreciated\nAbdomen: Soft, non-tender, non-distended, bowel sounds present,\nno organomegaly, no rebound or guarding  \nExt: Warm, well perfused, 2+ pulses, no clubbing, cyanosis. no \n___\nperipheral edema. Amputated ___ R toes with dried blood under\ndressing. Also with amputated L third toe.  \nNeuro: AAOx3, Face grossly symmetric. Moving all limbs with\npurpose against gravity. Not dysarthric. \n\n \nPertinent Results:\nAdmission labs:\n===============\n___ 01:30PM BLOOD WBC-7.2 RBC-2.45* Hgb-7.4* Hct-24.3* \nMCV-99* MCH-30.2 MCHC-30.5* RDW-17.0* RDWSD-61.7* Plt ___\n___ 01:30PM BLOOD Neuts-82.9* Lymphs-9.5* Monos-4.2* \nEos-2.7 Baso-0.3 Im ___ AbsNeut-5.93 AbsLymp-0.68* \nAbsMono-0.30 AbsEos-0.19 AbsBaso-0.02\n___ 01:30PM BLOOD ___ PTT-46.1* ___\n___ 01:30PM BLOOD ___\n___ 04:08PM BLOOD HIT Ab-NEG HIT ___\n___ 11:23AM BLOOD Ret Aut-2.2* Abs Ret-0.06\n___ 04:00PM BLOOD Glucose-117* UreaN-15 Creat-0.8 Na-141 \nK-4.3 Cl-96 HCO3-32 AnGap-13\n___ 04:00PM BLOOD ALT-<5 AST-19 LD(LDH)-303* CK(CPK)-81 \nAlkPhos-55 TotBili-0.2\n___ 01:30PM BLOOD CK-MB-6 proBNP-3592*\n___ 01:30PM BLOOD Calcium-8.3* Phos-3.0 Mg-1.5*\n___ 05:14AM BLOOD calTIBC-121* VitB12-463 Hapto-239* \nFerritn-257 TRF-93*\n___ 06:02AM BLOOD 25VitD-26*\n___ 07:25AM BLOOD ANCA-NEGATIVE B\n___ 07:25AM BLOOD CRP-18.1*\n___ 07:30AM BLOOD C3-119 C4-38\n\nKEY INTERVAL LABS:\n=====================\n___ 05:13AM BLOOD WBC-6.7 RBC-2.62* Hgb-8.0* Hct-25.5* \nMCV-97 MCH-30.5 MCHC-31.4* RDW-18.2* RDWSD-64.1* Plt ___\n___ 11:23AM BLOOD Ret Aut-2.2* Abs Ret-0.06\n___ 04:08PM BLOOD HIT Ab-NEG HIT ___\n___ 05:47AM BLOOD CK(CPK)-382*\n___ 05:07AM BLOOD CK(CPK)-206\n___ 04:24AM BLOOD CK(CPK)-145\n___ 12:16PM BLOOD cTropnT-0.29* proBNP-9716*\n___ 05:14AM BLOOD calTIBC-121* VitB12-463 Hapto-239* \nFerritn-257 TRF-93*\n___ 06:02AM BLOOD 25VitD-26*\n___ 07:25AM BLOOD ANCA-NEGATIVE B\n___ 07:25AM BLOOD CRP-18.1*\n___ 05:14AM BLOOD C3-76* C4-24\n___ 07:30AM BLOOD C3-119 C4-38\n\nMICROBIOLOGY:\n=============\n\n ___ 6:21 am STOOL     CONSISTENCY: SOFT     PRESENCE OF \nBLOOD.\n      Source: Stool. \n\n                            **FINAL REPORT ___\n\n   C. difficile PCR (Final ___: \n      Reported to and read back by ___ ON ___ AT \n1350. \n      POSITIVE.              (Reference Range-Negative). \n         The C. difficile PCR is highly sensitive for toxigenic \nstrains of\n         C. difficile and detects both C. difficile infection \n(CDI) and\n         asymptomatic carriage. Therefore, positive C. diff PCR \ntests\n         trigger reflex C. difficile toxin testing, which is \nhighly\n         specific for CDI. \n\n   FECAL CULTURE - R/O E.COLI 0157:H7 (Final ___: \n      No E. coli O157:H7 found. \n\n   C. difficile Toxin antigen assay (Final ___: \n      POSITIVE.              (Reference Range-Negative).  \nPERFORMED BY EIA. \n         This result indicates a high likelihood of C. difficile \ninfection\n         (CDI). \n\n___ 6:47 pm BLOOD CULTURE\n\n                           **FINAL REPORT ___\n\n   Blood Culture, Routine (Final ___: \n      ENTEROCOCCUS FAECIUM.    FINAL SENSITIVITIES. \n         Daptomycin MIC OF 4 MCG/ML test result performed by \nEtest. \n         ___ ___ (___) REQUESTS TETRACYCLINE ON ___. \n         TETRACYCLINE IS NOT APPRORIATE FOR PRIMARY THERAPY OF \nBLOODSTREAM\n         INFECTIONS.. \n         ORGANISMS THAT ARE SUSCEPTIBLE TO TETRACYCLINE ARE \nCONSIDERED\n         SUSCEPTIBLE TO MINOCYCLINE AND DOXYCYCLINE.. \n\n                              SENSITIVITIES: MIC expressed in \nMCG/ML\n                      \n_________________________________________________________\n                             ENTEROCOCCUS FAECIUM\n                             |   \nAMPICILLIN------------  =>32 R\nDAPTOMYCIN------------       S\nLINEZOLID-------------     2 S\nPENICILLIN G----------  =>64 R\nTETRACYCLINE----------  =>16 R\nVANCOMYCIN------------  =>32 R\n\n   Anaerobic Bottle Gram Stain (Final ___: \n      GRAM POSITIVE COCCI IN PAIRS AND CHAINS. \n      Reported to and read back by ___ (___) AT 1054 \nAM \n___. \n\n   Aerobic Bottle Gram Stain (Final ___: \n      GRAM POSITIVE COCCI IN PAIRS AND CHAINS. \n\n                            **FINAL REPORT ___\n\n   Blood Culture, Routine (Final ___: \n      ENTEROCOCCUS FAECIUM. \n         Identification and susceptibility testing performed on \nculture # \n         ___ ___. \n\n   Anaerobic Bottle Gram Stain (Final ___: \n      GRAM POSITIVE COCCI IN PAIRS AND CHAINS. \n\n   Aerobic Bottle Gram Stain (Final ___: \n      GRAM POSITIVE COCCI IN PAIRS AND CHAINS.\n\n___ 12:11 am URINE      Source: ___. \n\n                            **FINAL REPORT ___\n\n   URINE CULTURE (Final ___: \n      ENTEROCOCCUS SP..    >100,000 CFU/mL. \n\n                              SENSITIVITIES: MIC expressed in \nMCG/ML\n                      \n_________________________________________________________\n                             ENTEROCOCCUS SP.\n                             |   \nAMPICILLIN------------  =>32 R\nLINEZOLID-------------     2 S\nNITROFURANTOIN--------    64 I\nTETRACYCLINE----------  =>16 R\nVANCOMYCIN------------  =>32 R\n\n___ 1:05 am BLOOD CULTURE\n\n                            **FINAL REPORT ___\n\n   Blood Culture, Routine (Final ___: \n      ENTEROCOCCUS FAECIUM. \n         Identification and susceptibility testing performed on \nculture # \n         ___ ___. \n\n   Anaerobic Bottle Gram Stain (Final ___: \n      GRAM POSITIVE COCCI IN PAIRS AND CHAINS. \n\n   Aerobic Bottle Gram Stain (Final ___: \n      GRAM POSITIVE COCCI IN PAIRS AND CHAINS. \n\n___ 5:12 am URINE      Source: Catheter. \n\n                            **FINAL REPORT ___\n\n   URINE CULTURE (Final ___:    NO GROWTH.\n\n___ 2:46 am BLOOD CULTURE      Source: Venipuncture. \n\n                            **FINAL REPORT ___\n\n   Blood Culture, Routine (Final ___:    NO GROWTH. \n\n___ 4:52 am BLOOD CULTURE\n\n                            **FINAL REPORT ___\n\n   Blood Culture, Routine (Final ___:    NO GROWTH. \n\n___ 12:16 pm BLOOD CULTURE      Source: Line-pic. \n\n                            **FINAL REPORT ___\n\n   Blood Culture, Routine (Final ___:    NO GROWTH.  \n\nRELEVANT IMAGING:\n================\n___\nIMPRESSION:  \n  \nNo evidence of deep vein thrombosis in the left upper extremity. \n\n  \n___ \nIMPRESSION: Suboptimal image quality. Mild LVH with normal LV \nsystolic function. Well seated bioprosthetic aortic valve with \nnormal gradient. Trace aortic regurgitation. At least mild to\nmoderate mitral regurgitation, may be underestimated. Mild \ntricuspid regurgitaiton. Mild pulmonary hypertension. Resting \ntachycardia in setting of apparent atrial fibrillation.\nCompared with the prior TTE (images reviewed) of ___ \nprevious study is limited with suboptimal image quality limiting \ncomparison. Current gradient across the bioprostetic aortic \nvalve is normal. LVOT\ndiameter meausurement likely underestimated on prior. MR not \nwell assessed on prior.\n\nRECOMMEND: If clinically indicated, a TEE is suggested for \nfurther evaluation of endocarditis.\n\n___ \nIMPRESSION: \n  \n  \n1. No acute hemorrhage or evidence for other acute intracranial \nabnormalities. \nNo findings to suggest intracranial abscess on noncontrast CT. \n2. Small amount of fluid in the left mastoid tip air cells, \nwhich may be \nsecondary to prolonged supine positioning in the inpatient \nsetting.  Infection cannot be excluded in the setting of \nbacteremia.  However, no evidence for mastoid septal erosion to \nsuggest confluent mastoiditis. \n  \n___ CT chest w/o contrast\nIMPRESSION:  \n  \nCombination of pulmonary edema and infectious process. \n  \nBilateral pleural effusions, loculated on the left, small and \nminimal on the right.  Adjacent areas of atelectasis in \nparticular in the left lower lung. \n  \nNo appreciable abnormalities in the upper abdomen. \n  \nStatus post aortic valve replacement, extensive Coronary \ncalcifications, most likely previous CABG. \n\n___ TEE \nSmall mobile mass on the posterior mitral valve leaflet which \nmay represent\nmitral valve endocarditis or thrombus. Well-seated, normally \nfunctioning bioprosthetic aortic valve. Cannot exclude \nbioprosthetic aortic valve endocarditis. Mild mitral \nregurgitation. Simple\natheroma in the aortic arch with complex atheroma in the \ndescending thoracic aorta.\nCompared with the prior TEE ___, the small mitral valve \nmass seen on this study is not clearly visualized on the prior. \nDefinitive comparison of the possible bioprosthetic aortic valve \nmass\ncannot be made due to limited views on the prior study. There is \nless mitral regurgitation on this study.\nOther findings are similar.\n\n___ ___\n  \nIMPRESSION:  \n  \nNo evidence of deep venous thrombosis in the right or left lower \nextremity \nveins. \n\n___ CXR\nIMPRESSION:  \n  \nThere is no evidence of acute intracranial process or \nhemorrhage. \n  \n___ TTE\nThere is no evidence for a right-to-left shunt with agitated \nsaline at rest. Overall left ventricular systolic\nfunction is normal. Mildly dilated right ventricular cavity with \nmoderate global free wall hypokinesis. An aortic\nvalve bioprosthesis is present. The prosthesis is well seated \nwith normal leaflet motion. The mitral valve\nleaflets are mildly thickened. The tricuspid valve leaflets \nappear structurally normal. There is mild [1+]\ntricuspid regurgitation. There is mild pulmonary artery systolic \nhypertension.\nIMPRESSION: No right-to-left flow of agitated saline at rest. \nRight ventricular cavity dilation with\nfree wall hypokinesis. Well seated bioprosthetic aortic valve.\n\n___ CHEST (PORTABLE AP)  \nMostly resolved consolidation in the right upper lobe.  Some \nimprovement in left basilar opacification.  Similar diffuse \ninterstitial abnormality. \n\nDISCHARGE LABS\n==============\n___ 05:13AM BLOOD WBC-6.7 RBC-2.62* Hgb-8.0* Hct-25.5* \nMCV-97 MCH-30.5 MCHC-31.4* RDW-18.2* RDWSD-64.1* Plt ___\n___ 05:13AM BLOOD Glucose-124* UreaN-13 Creat-1.0 Na-143 \nK-3.7 Cl-103 HCO3-28 AnGap-12\n___ 04:00AM BLOOD WBC-10.3* RBC-2.73* Hgb-8.3* Hct-27.1* \nMCV-99* MCH-30.4 MCHC-30.6* RDW-18.2* RDWSD-65.6* Plt ___\n___ 04:00AM BLOOD Plt ___\n___ 04:00AM BLOOD Glucose-167* UreaN-14 Creat-1.2 Na-140 \nK-3.7 Cl-104 HCO3-28 AnGap-8*\n___ 04:00AM BLOOD Calcium-8.4 Phos-4.0 Mg-2.2\n\n \nBrief Hospital Course:\n===========================\nTRANSITIONAL ISSUES \n===========================\n[] Please encourage Mr. ___ to get a sleep study at next \nPCP follow up. ___ seems to be a longstanding problem that has \naffected his quality of life. \n[] Repeat CBC in 1 week to monitor anemia and WBC. Discharged \nwith WBC 10.3 (from 6.7) without any new infectious symptoms\n[] Please schedule colonoscopy given anemia and episode BRBPR \nearly on in hospitalization.\n[] Please continue taking daptomycin to be finished ___ ___s PO vancomycin, to be finished 10 days after completion of \ndaptomycin on ___.\n[] Trend CK level biweekly (next check ___ need to alter \nDaptomycin dosing vs. transition to another agent\n[] Holding statin while on Daptomycin. Resume once finished. \n\n===========================\nBRIEF SUMMARY \n===========================\n___ PMH HTN, AS s/p AVR (tissue), AFib on warfarin, DM, recent \nadmission for multi-organ dysfunction ___ emboli from aortic \natheroma and sepsis, CVA, rhabdomyolysis, ___ requiring CRRT, \nNSTEMI, ischemic toe, who was transferred from a long-term acute \ncare hospital due to acute onset of scattered macules throughout \nlower extremities diagnosed with leukocytoclastic vasculitis. He \nwas treated for bloodstream infection ___ VRE with IV Daptomycin \nwith course further complicated by acute hypoxemic respiratory \nfailure ___ HFpEF exacerbation, ___, anemia, and afib with RVR.\n\n#Acute on Chronic Hypoxic Resp Failure\n#HFpEF (EF>55%)\nAcute decompensated on the floor with SpO2 to the ___ requiring \nNRB, stabilized on high flow nasal cannula and weaned to 4L O2 \nby NC with diuresis. Etiology of decompensation thought to be \nDAH given hemoptysis and severe thrombocytopenia, and pulm edema \ngiven CXR with stable pulm vascular congestion. Chest CT with \nmultifocal infiltrates likely hemorrhage or aspiration \npneumonitis. CTA was negative for PE. DAH resolved given \nimproved platelet count. Volume overload treated with diuresis, \ninitially IV lasix descalated to Torsemide PO.\n\n# VRE bacteremia\n# Presumed endocarditis\nPossible prosthetic aortic valve endocarditis on TEE in ICU. Was \npreviously on IV dapto and Ceftaroline for synergistic effect on \nVRE, but ceftaroline d/c ___ for concern for DITP as below. \ntreated with IV daptomycin (___) with bi-weekly CK checks \nper ID recommendations. If CK continues to rise, may require \nalternative regimen or further daptomycin adjustments \n\n# AFib \n# Tachycardia\nCHADS2Vasc = 6. Chronic AFib with multiple potential rhythms, \nincluding AFib (rate controlled in ___ and ATach vs. Aflutter \n(rate 130s). Several self-resolving episodes of RVR this \nadmission. Started warfarin on last admission due to showering \nemboli. Pt switched to heparin gtt at the beginning of this\nadmission, then to apixaban (___) which was discontinued during \nepside of DITP and subsequent DAH. Apixiban restarted ___ with \nreturn of normal platelet count and no further episodes of \nhemoptysis or overt bleeding. Rate controlled in 90-110s with \nmetopolol 50 mg Q6H and diltiazem 30 mg TID.\n\n#Asymptomatic Severe Thrombocytopenia - resolved\n#Acute blood loss anemia\nOn ___ patient had precipitous drop in platelets from 156 -> 23 \nof initially unclear etiology. Heme/onc was consulted and felt \nthis was not likely a hemolytic process and most likely \ndrug-induced from either flagyl or ceftaroline (both stopped). \nHIT antibody screen negative, fibrinogen and haptoglobin normal.\nRequired total of 2U pletelets. Also had intermittently \ndowntrending hgb over this admission thought to be slow GI \noozing from severe C. diff. Received 1u pRBCS on ___ and again \n___. Platelets returned to ___ ___. H/H remained stable \nafter which. Will need outpatient colonoscopy \n\n# CAD s/p CABG (LIMA-LAD, SVG-RCA)\n# PVD\nContinued home ASA, but held home atorvastatin given daptomycin \nuse.\n\n# C diff\n# Frequent loose bowel movements\nToxin and PCR positive ___, coincided with onset of multiple \nsoft stools with small amount of blood. Also had decrease in \ndiarrhea following removal of ceftaroline suggesting abx \nassociated diarrhea. Started PO vancomycin with resolution of \ndiarrhea once transferred to medicine floor. PO vancomycin to be \ncontinued through ___.\n\n#Anxiety\nPatient has a history of anxiety and follows psychiatry \noutpatient. On sertraline at home. Related that he had been \nincreasingly anxious since admission given his deterioration in \nhealth. Started seroquel 25 mg QHS:prn as well as trazaodone and \nramelteon for sleep with improvement in mood. Avoided \nbenzodiazepines and placed patient on delirium precautions. Held \noff on Seroquel on discharge as patient not using, but could \nconsider if persistent anxiety.\n\nCHRONIC/RESOLVED ISSUES:\n========================\n# Leukocytoclastic vasculitis\nLikely ___ cefazolin vs. infectious etiology on admission. Rash \nhad resolved by time of transfer to medicine floor.\n\n# Elevated troponin\nElevated on presentation, 0.48 -> 0.52, peak TNT 0.61. Likely \ndue\nto demand ischemia, with ED EKG difficult to interpret and\nsubsequent EKG showing no ischemic changes.\n\n# T2DM\nContinued ISS.\n\nCORE MEASURES \n=============\n# CODE: Full code\n# CONTACT: ___ (HCP, wife), ___\n\n>30 min spent on dc related activities\n\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Acetaminophen 650 mg PO Q6H:PRN Pain - Mild/Fever \n2. Albuterol 0.083% Neb Soln 1 NEB IH Q6H:PRN SOB/wheezing \n3. Aspirin 81 mg PO DAILY \n4. Atorvastatin 80 mg PO QPM \n5. Bisacodyl 10 mg PO/PR DAILY:PRN Constipation - Second Line \n6. Brimonidine Tartrate 0.15% Ophth. 1 DROP BOTH EYES Q8H \n7. Lidocaine 5% Patch 1 PTCH TD QAM \n8. Neomycin-Polymyxin-Bacitracin 1 Appl TP PRN with all dressing \nchanges \n9. Omeprazole 20 mg PO BID \n10. OxyCODONE (Immediate Release) 5 mg PO Q8H:PRN Pain - \nModerate \n11. Polyethylene Glycol 17 g PO DAILY \n12. Ramelteon 8 mg PO QHS:PRN sleep \n13. Senna 8.6 mg PO BID \n14. Ascorbic Acid ___ mg PO DAILY \n15. Calcium Carbonate 500 mg PO BID \n16. CeFAZolin 2 g IV Q8H \n17. Dextrose 50% 12.5 gm IV PRN hypoglycemia protocol \n18. Diltiazem 30 mg PO Q6H \n19. Multivitamins W/minerals 1 TAB PO DAILY \n20. Sodium Chloride 0.9%  Flush ___ mL IV DAILY and PRN, line \nflush \n21. Vitamin D 1000 UNIT PO DAILY \n22. Zinc Sulfate 220 mg PO DAILY \n23. Sarna Lotion 1 Appl TP QID:PRN itching \n24. Simethicone 80 mg PO QID:PRN Bloating \n25. TraZODone 25 mg PO QHS:PRN Sleep \n26. Sertraline 25 mg PO DAILY \n27. Ipratropium Bromide Neb 1 NEB IH Q6H:PRN dyspnea \n28. Metoprolol Tartrate 62.5 mg PO Q6H \n29. ___  MD to order daily dose PO DAILY16 \n30. Glargine 8 Units Bedtime\n31. Furosemide 40 mg IV BID \n32. GuaiFENesin ER 600 mg PO Q12H \n33. Magnesium Oxide 400 mg PO BID \n\n \nDischarge Medications:\n1.  Apixaban 5 mg PO BID  \n2.  Daptomycin 900 mg IV Q24H infection  \n3.  Tamsulosin 0.4 mg PO QHS  \n4.  Torsemide 40 mg PO DAILY  \n5.  Vancomycin Oral Liquid ___ mg PO BID c. diff  \n6.  Diltiazem 30 mg PO TID  \n7.  Glargine 12 Units Bedtime\nInsulin SC Sliding Scale using HUM Insulin \n8.  Metoprolol Tartrate 50 mg PO Q6H  \n9.  Acetaminophen 650 mg PO Q6H:PRN Pain - Mild/Fever  \n10.  Albuterol 0.083% Neb Soln 1 NEB IH Q6H:PRN SOB/wheezing  \n11.  Ascorbic Acid ___ mg PO DAILY  \n12.  Aspirin 81 mg PO DAILY  \n13.  Bisacodyl 10 mg PO/PR DAILY:PRN Constipation - Second Line  \n\n14.  Brimonidine Tartrate 0.15% Ophth. 1 DROP BOTH EYES Q8H  \n15.  Calcium Carbonate 500 mg PO BID  \n16.  Dextrose 50% 12.5 gm IV PRN hypoglycemia protocol  \n17.  GuaiFENesin ER 600 mg PO Q12H  \n18.  Ipratropium Bromide Neb 1 NEB IH Q6H:PRN dyspnea  \n19.  Lidocaine 5% Patch 1 PTCH TD QAM  \n20.  Magnesium Oxide 400 mg PO BID  \n21.  Multivitamins W/minerals 1 TAB PO DAILY  \n22.  Neomycin-Polymyxin-Bacitracin 1 Appl TP PRN with all \ndressing changes  \n23.  Omeprazole 20 mg PO BID  \n24.  OxyCODONE (Immediate Release) 5 mg PO Q8H:PRN Pain - \nModerate  \n25.  Polyethylene Glycol 17 g PO DAILY  \n26.  Ramelteon 8 mg PO QHS:PRN sleep \nShould be given 30 minutes before bedtime  \n27.  Sarna Lotion 1 Appl TP QID:PRN itching  \n28.  Senna 8.6 mg PO BID  \n29.  Sertraline 25 mg PO DAILY  \n30.  Simethicone 80 mg PO QID:PRN Bloating  \n31.  Sodium Chloride 0.9%  Flush ___ mL IV DAILY and PRN, line \nflush  \n32.  TraZODone 25 mg PO QHS:PRN Sleep  \n33.  Vitamin D 1000 UNIT PO DAILY  \n34.  Zinc Sulfate 220 mg PO DAILY  \n35. HELD- Atorvastatin 80 mg PO QPM  This medication was held. \nDo not restart Atorvastatin until you follow up with your doctor \ndue to reaction with Daptomycin\n\n1.  Apixaban 5 mg PO BID \nRX *apixaban [Eliquis] 5 mg 1 tablet(s) by mouth twice a day \nDisp #*60 Tablet Refills:*0 \n2.  Daptomycin 900 mg IV Q24H infection  \n3.  Tamsulosin 0.4 mg PO QHS  \n4.  Torsemide 40 mg PO DAILY  \n5.  Vancomycin Oral Liquid ___ mg PO BID c. diff  \n6.  Diltiazem 30 mg PO TID  \n7.  Glargine 12 Units Bedtime\nInsulin SC Sliding Scale using HUM Insulin \n8.  Metoprolol Tartrate 50 mg PO Q6H  \n9.  Acetaminophen 650 mg PO Q6H:PRN Pain - Mild/Fever  \n10.  Albuterol 0.083% Neb Soln 1 NEB IH Q6H:PRN SOB/wheezing  \n11.  Ascorbic Acid ___ mg PO DAILY  \n12.  Aspirin 81 mg PO DAILY  \n13.  Bisacodyl 10 mg PO/PR DAILY:PRN Constipation - Second Line  \n\n14.  Brimonidine Tartrate 0.15% Ophth. 1 DROP BOTH EYES Q8H  \n15.  Calcium Carbonate 500 mg PO BID  \n16.  Dextrose 50% 12.5 gm IV PRN hypoglycemia protocol  \n17.  GuaiFENesin ER 600 mg PO Q12H  \n18.  Ipratropium Bromide Neb 1 NEB IH Q6H:PRN dyspnea  \n19.  Lidocaine 5% Patch 1 PTCH TD QAM  \n20.  Magnesium Oxide 400 mg PO BID  \n21.  Multivitamins W/minerals 1 TAB PO DAILY  \n22.  Neomycin-Polymyxin-Bacitracin 1 Appl TP PRN with all \ndressing changes  \n23.  Omeprazole 20 mg PO BID  \n24.  OxyCODONE (Immediate Release) 5 mg PO Q8H:PRN Pain - \nModerate  \n25.  Polyethylene Glycol 17 g PO DAILY  \n26.  Ramelteon 8 mg PO QHS:PRN sleep \nShould be given 30 minutes before bedtime  \n27.  Sarna Lotion 1 Appl TP QID:PRN itching  \n28.  Senna 8.6 mg PO BID  \n29.  Sertraline 25 mg PO DAILY  \n30.  Simethicone 80 mg PO QID:PRN Bloating  \n31.  Sodium Chloride 0.9%  Flush ___ mL IV DAILY and PRN, line \nflush  \n32.  TraZODone 25 mg PO QHS:PRN Sleep  \n33.  Vitamin D 1000 UNIT PO DAILY  \n34.  Zinc Sulfate 220 mg PO DAILY  \n35. HELD- Atorvastatin 80 mg PO QPM  This medication was held. \nDo not restart Atorvastatin until you follow up with your doctor \ndue to reaction with Daptomycin\n\n \nDischarge Disposition:\nExtended Care\n \nFacility:\n___\n \nDischarge Diagnosis:\nRash (leukocytoclastic vasculitis)\nHeart Failure \nBloodstream Infection\nUrinary Tract Infection\nAtrial Fibrillation\nSleep Apnea\n\n \nDischarge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Out of Bed with assistance to chair or \nwheelchair.\n\n \nDischarge Instructions:\nDear Mr. ___, \n\n===================================\nWHY DID YOU COME TO THE HOSPITAL?\n===================================\nYou came to the hospital for a rash on your legs.\n\n================================\nWHAT HAPPENED AT THE HOSPITAL?\n================================\n-Your rash was evaluated by the dermatology and vascular surgery \nteams. \n-You were found to have a bloodstream infection, which was \ntreated with antibiotics.\n-Your heart failure was treated with medications\n-You were given oxygen to help with your breathing. \n-Your blood counts were low and we gave you units of blood to \nbring your counts back up. \n-You had a urinary tract infection which was treated with \nantibiotics.\n-You had a bleed in your lungs that was a result of low \nplatelets caused by a reaction to some of the antibiotics you \nwere initially on\n-Your atrial fibrillation was better controlled with medications \nand anticoagulation\n\n====================================================\nWHAT NEEDS TO HAPPEN WHEN YOU LEAVE THE HOSPITAL?\n=====================================================\n-Please follow up with your primary care physician as below.\n-If you notice any of the danger signs listed below, please \ncontact your PCP or go to an emergency room immediately.\n\nIt was a pleasure taking care of you during your stay!\n\nSincerely, \n\nYour ___ medical team \n \nFollowup Instructions:\n___\n",
  "boolean_questions": {
    "qafib": {
      "criterion": "afib",
      "question": "Does the note describe the patient as having permanent, paroxysmal, or persistent afib?",
      "answer": "Yes",
      "not_specified": false
    },
    "qprior_stroke": {
      "criterion": "prior_stroke",
      "question": "Does the note describe the patient as ever having a stroke or transient ischemic attack?",
      "answer": "No",
      "not_specified": false
    },
    "qarterial_hypertension": {
      "criterion": "arterial_hypertension",
      "question": "Does the note describe the patient as having arterial hypertension on treatment (high bp e.g. >140, or HTN)?",
      "answer": "Yes",
      "not_specified": false
    },
    "qt2d": {
      "criterion": "t2d",
      "question": "Does the note describe the patient as having Diabetes mellitus (DM1, DM2, T2D, T1DM, T2DM)?",
      "answer": "Yes",
      "not_specified": false
    },
    "qheart_failure": {
      "criterion": "heart_failure",
      "question": "Does the note describe the patient as having heart failure?",
      "answer": "Yes",
      "not_specified": false
    },
    "qsurgical_valvular_disease": {
      "criterion": "surgical_valvular_disease",
      "question": "Does the note describe the patient as ever having valvular disease requiring surgery (stenosis)?",
      "answer": "Yes",
      "not_specified": false
    },
    "qafib_ablation": {
      "criterion": "afib_ablation",
      "question": "Does the note describe the patient as having a planned or past ablation procedure for afib?",
      "answer": "No",
      "not_specified": false
    },
    "qbleeding": {
      "criterion": "bleeding",
      "question": "Does the note describe the patient as having a serious bleeding in the past 6 months?",
      "answer": "Yes",
      "not_specified": false
    },
    "qpeptic_ulcer_disease": {
      "criterion": "peptic_ulcer_disease",
      "question": "Does the note describe the patient as ever having peptic ulcer disease?",
      "answer": "No",
      "not_specified": false
    },
    "qrecent_stroke": {
      "criterion": "recent_stroke",
      "question": "Does the note describe the patient as having a stroke during this admission or within the last month? (Answer yes for any recent stroke if the date is unclear)",
      "answer": "No",
      "not_specified": false
    },
    "qhemorrhagic": {
      "criterion": "hemorrhagic",
      "question": "Does the note describe the patient as ever having any hemorrhagic tendencies or blood dyscrasias?",
      "answer": "No",
      "not_specified": false
    },
    "qbipolar": {
      "criterion": "bipolar",
      "question": "Does the note describe the patient as ever being diagnosed with bipolar disorder?",
      "answer": "No",
      "not_specified": false
    },
    "qschizophrenia": {
      "criterion": "schizophrenia",
      "question": "Does the note describe the patient as ever being diagnosed with schizophrenia or any schizoaffective disorders?",
      "answer": "No",
      "not_specified": false
    },
    "qmdd": {
      "criterion": "mdd",
      "question": "Does the note describe the patient as ever being diagnosed with depression or major depressive disorder (MDD)?",
      "answer": "No",
      "not_specified": false
    },
    "qmed_decisions": {
      "criterion": "med_decisions",
      "question": "Does the note describe the patient as being unable to make medical decisions? (Answer no unless there is evidence the patient cannot make their own medical decisions).",
      "answer": "No",
      "not_specified": false
    }
  },
  "numeric_questions": {
    "qchads2": {
      "criterion": "chads2",
      "question": "What is the highest CHADS2 score mentioned? Answer \"NA\" if no CHADS2 score is in the note. ",
      "answer": "6",
      "not_specified": false
    },
    "qblood_glucose": {
      "criterion": "blood_glucose",
      "question": "What is the highest blood glucose lab mentioned? Answer \"NA\" if no blood glucose score is in the note.",
      "answer": "167",
      "not_specified": false
    },
    "qlvef": {
      "criterion": "lvef",
      "question": "What is the lowest left ventricular ejection (LVEF, ef, ejection fraction) fraction mentioned in the note? Answer \"NA\" if no LVEF is in the note, Answer 55 if the lowest value is 55% or greater.",
      "answer": "55",
      "not_specified": false
    },
    "qPLT": {
      "criterion": "PLT",
      "question": "What is the lowest platelet count (PLT) mentioned in the note? Answer \"NA\" if no platelet count is available in the note.",
      "answer": "",
      "not_specified": false
    },
    "qHGB": {
      "criterion": "HGB",
      "question": "What is the lowest hemoglobin (HGB) mentioned in the note? Answer \"NA\" if no HGB value is available in the note.",
      "answer": "7.4",
      "not_specified": false
    },
    "qCREAT": {
      "criterion": "CREAT",
      "question": "What is the higest serum creatinine (Creat) mentioned in the note? Answer \"NA\" if no creatinine value is available in the note.",
      "answer": "1.2",
      "not_specified": false
    },
    "qAST": {
      "criterion": "AST",
      "question": "What is the higest aspartate aminotransferase level (AST) mentioned in the note? Answer \"NA\" if no AST value is available in the note.",
      "answer": "19",
      "not_specified": false
    },
    "qBILI": {
      "criterion": "BILI",
      "question": "What is the higest total bilirubin (TotBili, Bili) mentioned in the note? Answer \"NA\" if no bilirubin value is available in the note.",
      "answer": "0.2",
      "not_specified": false
    }
  },
  "patient_number": 61
}